ライフサイエンスコーパス: vascular resistance

1 ficant correlation between PED and pulmonary vascular resistance.

2 ue, in part, through reduction of peripheral vascular resistance.

3 cal pressure, and variations in the systemic vascular resistance.

4 creating transient hypoxemia and increasing vascular resistance.

5 ned by cardiac output (total flow) and total vascular resistance.

6 r smooth muscle cell activation and elevated vascular resistance.

7 oxygenation, and does not increase pulmonary vascular resistance.

8 tion, and lowers blood pressure and systemic vascular resistance.

9 tion are not deleterious in terms of in vivo vascular resistance.

10 duced in placentas associated with increased vascular resistance.

11 ved cardiac index and pulmonary and systemic vascular resistance.

12 output and less severely elevated pulmonary vascular resistance.

13 pite a significant decrease in the pulmonary vascular resistance.

14 ed resistance for venous return and systemic vascular resistance.

15 lood flow, suggesting a reduction in hepatic vascular resistance.

16 tal (cold) stress, and higher basal systemic vascular resistance.

17 aralleled by an initial increase in systemic vascular resistance.

18 x, end-systolic blood pressure, and systemic vascular resistance.

19 constant flow) provided an index of systemic vascular resistance.

20 ygenation while avoiding increased pulmonary vascular resistance.

21 sculature associated with elevated pulmonary vascular resistance.

22 y vasculature cause an increase in pulmonary vascular resistance.

23 hifts in response to head-up tilt and higher vascular resistance.

24 ulates blood pressure by altering peripheral vascular resistance.

25 vasculature, leading to increased pulmonary vascular resistance.

26 vascular remodeling and increased pulmonary vascular resistance.

27 lts in elevated blood pressure and increased vascular resistance.

28 rterial flow, indicating increased placental vascular resistance.

29 ively correlated (rho=-0.497) with pulmonary vascular resistance.

30 st amongst patients with the lowest systemic vascular resistance.

31 atrial pressure, cardiac index and pulmonary vascular resistance.

32 estimated from characteristic impedance and vascular resistance.

33 nced sodium retention and increased systemic vascular resistance.

34 occurred in patients with elevated pulmonary vascular resistance.

35 245 +/- 39 m; P < 0.05); decreased pulmonary vascular resistance (0.18 +/- 0.02 vs. 0.38 +/- 0.14 mm

36 per cm(-5); P<0.001), and isoflow pulmonary vascular resistance (124+/-74 dyne/s per cm(-5) versus 9

37 Patients with CSPH had lower systemic vascular resistance (1336 +/- 423 versus 1469 +/- 335 dy

38 93 +/- 2 mm Hg, flow 310 +/- 20 mL/min, and vascular resistance 153 +/- 16 mm Hg/L per minute.

39 5 [13.8] vs 56.4 [15.3] mm Hg) and pulmonary vascular resistance (16.6 [8.3] vs 12.9 [8.3] Wood units

40 ltration rate (21%, p<0.05), decreased renal vascular resistance (18%, p<0.05) but caused no signific

41 7 cm2, respectively; P<0.005), and pulmonary vascular resistance (2.4, 2.9, 3.6 woods units, respecti

42 14.5+/-3.5 mm Hg; P=0.05), higher pulmonary vascular resistance (2.6+/-1.6 versus 2.0+/-1.0 Wood uni

43 rkload with improved cardiac index and lower vascular resistance, 2) upgraded hearts' apelinergic res

44 interval of indirect effect including renal vascular resistance, -2.51 to -0.76).

45 nterval, -89.4 to -3.8; P=0.03) and systemic vascular resistance (-239.3 dynes.s(-1).cm(-5); 95% conf

46 3% predicted) and a higher resting pulmonary vascular resistance (247+/-101 versus 199+/-56 dyne x s

47 ptic shock associated with elevated systemic vascular resistance (2C); and use of hydrocortisone only

48 s 47 +/- 10 mm Hg, P < 0.0001) and pulmonary vascular resistance (3.0 +/- 1.4 versus 6.1 +/- 3.1 Wood

49 , 23.2-41.4]; P < 0.05) and median pulmonary vascular resistance (3.1 Wood units [IQR, 2.0-5.7] vs. 6

50 Patients who died had higher pulmonary vascular resistance (3.8 +/- 1.6 Wood units [WU] vs. 2.1

51 pillary pressure 18 (16-22) mm Hg, pulmonary vascular resistance 362 (235-603) dyn s cm(-5).

52 NO3(-) led to greater reductions in systemic vascular resistance (-42.4+/-16.6% versus -31.8+/-20.3%;

53 Among recipients with high pulmonary vascular resistance, 5-year survival was similar for tho

54 ad was similar in SScPAH and IPAH (pulmonary vascular resistance=7.0+/-4.5 versus 7.9+/-4.3 Wood unit

55 utation carriers 55+/-9 mm Hg) and pulmonary vascular resistance (755 [483-1043] versus 931 [624-1311

56 s 6.6 +/- 0.4 L/min, p < 0.05), but systemic vascular resistance (885 +/- 77 dyn.s/cm vs 531 +/- 29 d

57 e renal plasma flow and an increase in renal vascular resistance (all P<0.01).

58 eption of cardiac index and indexed systemic vascular resistance, all the other hepatic and systemic

59 be dynamic to avoid the increase in systemic vascular resistance and abrupt changes in intrathoracic

60 Kir2 channels also regulate vascular resistance and blood pressure.

61 Low systemic vascular resistance and bradycardia are also commonly se

62 endothelial glycocalyx) results in increased vascular resistance and disturbed endothelial nitric oxi

63 ranscription and secretion, raising systemic vascular resistance and early heritable responses to env

64 Furthermore, negative correlations between vascular resistance and hematocrit are observed in vario

65 ed by drug treatments that reduce peripheral vascular resistance and hypertension, consistent with th

66 The regenerated endothelium showed reduced vascular resistance and improved barrier function over t

67 ean pulmonary artery pressure, and pulmonary vascular resistance and increased cardiac output and ind

68 mean pulmonary artery pressure and pulmonary vascular resistance and increased cardiac output.

69 al and central venous pressures and systemic vascular resistance and increased heart rate, cardiac in

70 odelling are important for lowering maternal vascular resistance and increasing uteroplacental blood

71 Increased vascular resistance and left ventricular mass were the m

72 nsatory mechanism for the blunted peripheral vascular resistance and lower central volume.

73 relationship also existed between pulmonary vascular resistance and minimum septal curvature indexed

74 nspulmonary pressure gradient, and pulmonary vascular resistance and more pronounced ventilatory resp

75 RHC-confirmed PH who have elevated pulmonary vascular resistance and normal pulmonary capillary wedge

76 y arteries, resulting in increased pulmonary vascular resistance and pulmonary pressures.

77 Increased vascular resistance and reduced fetoplacental blood flow

78 nts mean systemic filling pressure, systemic vascular resistance and resistance for venous return inc

79 High pulmonary vascular resistance and right atrial pressure by invasiv

80 tion was associated with increased pulmonary vascular resistance and right ventricular dysfunction in

81 disease characterized by increased pulmonary vascular resistance and right ventricular failure; morbi

82 causes cor pulmonale with elevated pulmonary vascular resistance and secondary reductions in left ven

83 ion during HMP resulted in lower endischemic vascular resistance and slightly elevated free radical-m

84 In contrast, the decline in peripheral vascular resistance and the increase in nitric oxide are

85 Because RBC aggregation promotes vascular resistance and thrombosis, W could also provide

86 Pulmonary vascular resistance and vascular permeability measured i

87 or CPASMCs in controlling both fetoplacental vascular resistance and vasculogenesis.

88 ry arteries, resulting in elevated pulmonary vascular resistance and, eventually, in right ventricula

89 tly reduced systemic arterial compliance and vascular resistances and increased valvulo-arterial impe

90 lower arterial afterload (decreased systemic vascular resistance) and higher metabolic rate.

91 factors (cardiac output, blood pressure and vascular resistance) and how these change with sex and a

92 factant before EVLP returned PaO2, pulmonary vascular resistance, and apoptotic-cell percentage to sh

93 leads to endothelial dysfunction, increased vascular resistance, and arterial remodeling and stiffen

94 luding renal artery pulsatility index, renal vascular resistance, and arterial volume in the cortex,

95 r earlier central venous pressures, systemic vascular resistance, and changes in the BUN:Cr ratio(P <

96 levated cardiac stroke volume with decreased vascular resistance, and elevated pressor responses to e

97 arget genes, liver injury, increased hepatic vascular resistance, and endothelial dysfunction.

98 proved uterine blood flow, decreased uterine vascular resistance, and improved fetal weights in compa

99 , such as a lack of neural inputs, increased vascular resistance, and leukocyte activation.

100 evaluated by mean pulmonary artery pressure, vascular resistance, and limited vascular remodeling qua

101 Cardiac output, systemic vascular resistance, and mean arterial blood pressure we

102 sis, WHO functional class, indexed pulmonary vascular resistance, and pulmonary-to-systemic arterial

103 n adjusted for pulmonary pressure, pulmonary vascular resistance, and right atrial pressure and provi

104 stal pulmonary arteries, increased pulmonary vascular resistance, and right ventricular dysfunction t

105 the pediatric limits on acceptable pulmonary vascular resistance, and risk prediction of pediatric tr

106 enance of appropriate systemic and pulmonary vascular resistance, and surgical planning and anticoagu

107 arterial pressure*, systemic* and pulmonary* vascular resistances, and atrial natriuretic peptide*.

108 es, as well as indices of vascular function (vascular resistance, aortic input impedance, compliance,

109 in right ventricular (RV) mass and pulmonary vascular resistance as co-primary endpoints and stroke v

110 less than 10 L.min(-1) or a total pulmonary vascular resistance at exercise of less than 3 Wood unit

111 opolysaccharide binding protein and systemic vascular resistance below the mean (1,011 dynes x s/cm(5

112 put (beta=0.20, P<0.0001) and lower systemic vascular resistance (beta=-0.18, P<0.0001).

113 put (beta=-0.10, P<0.05) and higher systemic vascular resistance (beta=0.08, P<0.05), whereas lower b

114 Higher third trimester umbilical artery vascular resistance, but not uterine artery vascular res

115 Higher third trimester feto-placental vascular resistance, but not utero-placental vascular re

116 the hypoxic mouse lung and reduced pulmonary vascular resistance by attenuating vascular remodeling.

117 ardiac index (by 18%) and decreased systemic vascular resistance (by 11%), serum cholesterol (-20%),

118 mL; P=0.003), with marked falls in pulmonary vascular resistance (by 29%; P=0.03) and right atrial pr

119 cluding pulmonary artery pressure, pulmonary vascular resistance, capillary wedge pressure, and cardi

120 presence of pericardial effusion, pulmonary vascular resistance, cardiac index, and right atrial pre

121 for potential mediators including pulmonary vascular resistance, cardiac index, and vasoreactivity.

122 athetic activity may fail to produce greater vascular resistance changes in hypertensive rats because

123 increased cutaneous blood flow and decreased vascular resistance compared to changes induced by frequ

124 Coronary vascular resistance (CVR; mean arterial pressure/coronar

125 The pulmonary vascular resistance decreased along with the ratio of th

126 Pulmonary vascular resistance decreased by 226 dyn.sec.cm(-5) in t

127 Pulmonary vascular resistance decreased by 379 dyne.s.cm(-5) (95%

128 Pulmonary vascular resistance decreased with exercise in all contr

129 a late increase in heart rate, whereas total vascular resistance decreased.

130 th elevated vascular gradients and pulmonary vascular resistance defines combined post- and precapill

131 Carotid artery pressure, blood flow and vascular resistance did not change compared to fetuses r

132 unchanged in nonsurvivors, whereas pulmonary vascular resistance did not change in either group.

133 arguing a vital role for S1P in maintaining vascular resistance during recovery from circulatory sho

134 on the OCS system due to prohibitively high vascular resistance, edema, and worsening compliance.

135 In addition, upon warm reperfusion hepatic vascular resistance, endothelial function, nitric oxide

136 acterized by a progressive rise in pulmonary vascular resistance, eventually leading to right-heart f

137 e face of increased cardiac output, systemic vascular resistance fails to decline homeostatically.

138 BP in salt resistance, renal and peripheral vascular resistance falls and is associated with an incr

139 l (p < 0.001); and 3) a decrease in systemic vascular resistance from 1,226 +/- 481 dyn.s/cm(5) to 1,

140 lso occur in the setting of normal pulmonary vascular resistance from a high flow state and/or increa

141 5 mm Hg or greater, with increased pulmonary vascular resistance from portopulmonary hypertension, ha

142 es in heart rate, blood pressure and forearm vascular resistance (FVR) during submaximal LBNP.

143 valuated imatinib in patients with pulmonary vascular resistance >/= 800 dyne.s.cm(-5) symptomatic on

144 tery wedge pressure >15 mm Hg; (2) pulmonary vascular resistance >/=3.0 Wood units; or (3) inpatient

145 artery pressure of >/=38 mm Hg and pulmonary vascular resistance >/=425 dynes.s(-1).cm(-5) at reasses

146 c mitral annular velocity >14, and pulmonary vascular resistance >2.5 Wood units, accurately identifi

147 g) and 28 (34%) also had increased pulmonary vascular resistance >3.0 WU.

148 with increased mortality included pulmonary vascular resistance >32 Wood units (hazard ratio [HR], 4

149 nute walk distance </=450 m, and a pulmonary vascular resistance >800 dynes.s/cm(5), despite therapy

150 nary artery pressure, >/=25 mm Hg; pulmonary vascular resistance, >3.0 WU; pulmonary artery wedge pre

151 Elevated pulmonary vascular resistance has been associated with raised leve

152 interval, 1.03-1.13; P<0.01), and pulmonary vascular resistance (hazard ratio, 1.01; 95% confidence

153 ; 95% CI, 1.02-1.37; p = 0.03) and pulmonary vascular resistance (hazard ratio, 1.28 per interquartil

154 10 mm Hg increase; P = 0.011), and pulmonary vascular resistance (HR, 1.44; 95% CI, 1.09-1.89 per Woo

155 rect effect of INT-747 on total intrahepatic vascular resistance (IHVR) and intrahepatic vascular ton

156 sms that regulate the increased intrahepatic vascular resistance (IHVR) in cirrhosis.

157 In cirrhosis, increased intrahepatic vascular resistance (IHVR) is the primary factor for por

158 monary artery pressure and indexed pulmonary vascular resistance in children with pulmonary hypertens

159 cular remodeling and the increased pulmonary vascular resistance in hypoxic pulmonary hypertension.

160 owered mean arterial pressure and peripheral vascular resistance in patients and healthy control subj

161 te a model for estimating mPAP and pulmonary vascular resistance in patients with chronic thromboembo

162 tly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembo

163 between flow-mediated dilation and pulmonary vascular resistance in patients with HFpEF and PH (r=-0.

164 Instead, an increase in peripheral vascular resistance in these animals is considered possi

165 ecreased, and adrenal blood flow and femoral vascular resistance increased in all fetuses during hypo

166 Resistance for venous return and systemic vascular resistance increased more (p = 0.019 and p = 0.

167 ssure and pulse pressure, decreased systemic vascular resistance, increased aortic distensibility and

168 essure (-7 mm Hg; p = 0.041) and in systemic vascular resistance index (-116 dyne.sec/cm5/m2; p = 0.0

169 t (28 vs 11 cm H(2)O; P < .001) and systemic vascular resistance index (1610 vs 1384 dyn . sec . cm(-

170 , and heart rate (7%) and decreased systemic vascular resistance index (21%), whereas mean arterial p

171 - 0.79 mm Hg.m(2)/mL; P<0.0001) and systemic vascular resistance index (3116 +/- 799 versus 2515 +/-

172 A coronary vascular resistance index (CVR) was calculated as diasto

173 V FWHM, and LV TTP correlated with pulmonary vascular resistance index (P < .01), right ventricular s

174 ide (p = 0.001; 95% CI, 0.99-1.00), systemic vascular resistance index (p < 0.001; 95% CI, 0.97-0.99)

175 ducing mean arterial pressure and peripheral vascular resistance index (P<0.001 for all) irrespective

176 lmonary artery pressure (MPAP) and pulmonary vascular resistance index (PVRI) (by 9.6% and 20.8%, res

177 mean PAP (r = 0.62, P < .0014) and pulmonary vascular resistance index (PVRI) (r = 0.77, P < .0014).

178 he potential relationships between pulmonary vascular resistance index (PVRI) and Fontan failure have

179 endpoint was a fall from baseline pulmonary vascular resistance index (PVRi) of 20% or more over 16

180 =0.02) in the sildenafil group, and systemic vascular resistance index (resting, P=0.0002; peak exerc

181 n children and to analyze the correlation of vascular resistance index (RI) and the degree of vascula

182 oppler callus vascularity was visualized and vascular resistance index (RI) was measured.

183 The median pulmonary vascular resistance index (Rpi) was 6.0 WU/m(2).

184 al compliance (pulsatile load), and systemic vascular resistance index (steady load) were compared be

185 The aim was to investigate systemic vascular resistance index (SVRI), cardiac index, and myo

186 rtery occlusive pressure, PVRI, and systemic vascular resistance index but also in the PaO(2)/inspire

187 eptic sheep, MAP fell by ~30 mm Hg, systemic vascular resistance index decreased by ~50%, and ~7 L of

188 index (P=0.005) increased, whereas systemic vascular resistance index decreased during exercise (P<0

189 normothermia, leading to increased systemic vascular resistance index not seen at normothermia.

190 Pulmonary vascular resistance index was also an independent predic

191 Systemic vascular resistance index was not associated with diasto

192 Systemic vascular resistance index was reduced (P<0.0001-interact

193 pliance was lower in women, whereas systemic vascular resistance index was similar between sexes.

194 mean pulmonary artery pressure and pulmonary vascular resistance index were 56 mm Hg and 17 Wood unit

195 changes in stroke volume index and systemic vascular resistance index were measured within the first

196 total arterial compliance, Ca; and systemic vascular resistance index) in patients with LGSAS (mean

197 ulmonary artery occlusive pressure, systemic vascular resistance index, and PVRI, whereas cardiac ind

198 nal pro-B-type natriuretic peptide, systemic vascular resistance index, and stroke volume index on da

199 When controlling for pulmonary vascular resistance index, graft ischemic time, and card

200 icular systolic pressure and total pulmonary vascular resistance index, increased pulmonary artery ac

201 al from enrollment included higher pulmonary vascular resistance index, lower-weight z scores, and fa

202 ased on whether their preoperative pulmonary vascular resistance indicated severe or nonsevere chroni

203 iance remains predictive even when pulmonary vascular resistance is normal.

204 fined by a progressive increase in pulmonary vascular resistance leading to right-sided heart failure

205 AP minus mean PAWP) <12 mm Hg, and pulmonary vascular resistance </=3 Wood units (WU).

206 cardiac output with no changes in peripheral vascular resistance may contribute to (pre)syncope.

207 -12%; P<0.001) and pulmonary (-29%; P=0.002) vascular resistance, mean pulmonary artery (-25%; P<0.00

208 monstrated a significant correlation between vascular resistance measured in vivo and ex vivo in norm

209 y may significantly influence the intrarenal vascular resistance measured using Doppler sonography in

210 clearance (index of GFR) and increased renal vascular resistance (measured by transit time nanoprobes

211 pressure and arterial elastance (measure of vascular resistance) more than tripled in PH.

212 included changes from baseline in pulmonary vascular resistance, N-terminal pro-brain natriuretic pe

213 end points included the change in pulmonary vascular resistance, N-terminal pro-brain natriuretic pe

214 expression of RyRs between SMCs of the same vascular resistance network.

215 e arterioles and feed arteries that comprise vascular resistance networks.

216 ese findings suggest that increased PASP and vascular resistance observed at HA are associated with a

217 pressure of 22.6+/-8.9 mm Hg, and pulmonary vascular resistance of 4.6+/-2.9 Wood units.

218 ogenic biomarkers in the control of maternal vascular resistance of preeclampsia.

219 ability of astronauts to augment peripheral vascular resistance, often resulting in orthostatic hypo

220 ic sinus eddy vortices and variable systemic vascular resistance on overall valve opening-closing dyn

221 ce was overestimated by calculated pulmonary vascular resistance on the basis of PC-MRI in comparison

222 d by other mechanisms that increase coronary vascular resistance or reduce coronary driving pressure.

223 ed physiological variables (lung compliance, vascular resistance, oxygenation capacity), lung weight

224 ght atrial pressure (P = 0.02) and pulmonary vascular resistance (P = 0.01) in men with PAH.

225 rain was associated with increased pulmonary vascular resistance (P<0.0001) and decreased peak oxygen

226 e were significant improvements in pulmonary vascular resistance (P<0.001), NT-proBNP levels (P<0.001

227 flow was related to the decrease in systemic vascular resistance (P=0.03), increase in total arterial

228 pulmonary arterial compliance and pulmonary vascular resistance predict mortality in acute respirato

229 intolerance is multifactorial, but pulmonary vascular resistance probably plays a crucial role.

230 activity is an efficient mechanism to raise vascular resistance promptly, corroborating its involvem

231 y hypertension in mice, decreasing pulmonary vascular resistance, pulmonary artery remodeling, and ri

232 3 versus 29 +/- 2 (Cstat-cm H2O), pulmonary vascular resistance (PVR) 593 +/- 127 versus 495 +/- 70

233 g patients with primarily elevated pulmonary vascular resistance (PVR) from those with PH predominant

234 ry pulse pressure), in relation to pulmonary vascular resistance (PVR) in heart failure.

235 tor acute and long-term changes in pulmonary vascular resistance (PVR) noninvasively.

236 WHO functional class II-IV with a pulmonary vascular resistance (PVR) of at least 400 dyn.s/cm(5) an

237 e, the transpulmonary gradient and pulmonary vascular resistance (PVR) were elevated in the ePH and e

238 he primary end point was change in pulmonary vascular resistance (PVR) with exercise.

239 ly reduces pulmonary pressures and pulmonary vascular resistance (PVR), effects reverse right ventric

240 edure depends in large part on low pulmonary vascular resistance (PVR).

241 ry arterial pressure >25 mm Hg and pulmonary vascular resistance [PVR] >/=240 dynes.s.cm) who were ap

242 atrial pressure, mean PA pressure, pulmonary vascular resistance [PVR], and PVR and PA pressure-flow

243 WSS in the CCA correlated with the change in vascular resistance (r = -0.85, P < .001).

244 olume (r = 0.660; p < 0.0001), and pulmonary vascular resistance (r = 0.643; p = 0.001) correlated si

245 , unlike the systemic circulation, pulmonary vascular resistance (R(PA)) and compliance (C(PA)) are c

246 h degree of PH (r=0.66; P<0.0001), pulmonary vascular resistance (r=0.60; P<0.0001), and right ventri

247 y gradient (r=0.560; P=0.013), and pulmonary vascular resistance (r=0.626; P=0.004).

248 cular-pulmonary arterial coupling (pulmonary vascular resistance: R=-0.36; P<0.01; right ventricular

249 , which were coupled with increased cerebral vascular resistance, reduced cerebral blood flow, and a

250 decreased cardiac index, increased systemic vascular resistance, reduced portal pressure (PP), super

251 P ratio was associated with higher pulmonary vascular resistance, reduced RV function (manifest as a

252 mean pulmonary artery pressure and pulmonary vascular resistance, respectively (r=0.58 and -0.74; P<0

253 rterial volume in the cortex or higher renal vascular resistance, respectively, when offered as media

254 ion, and function through reduction in renal vascular resistance, reversal of endothelial dysfunction

255 modeling that results in increased pulmonary vascular resistance, right ventricular (RV) failure, and

256 arteries, leading to elevation of pulmonary vascular resistance, right ventricular failure and death

257 Furthermore, PYR reduced pulmonary vascular resistance, RV afterload, and pulmonary vascula

258 A medication capable of decreasing pulmonary vascular resistance should allow improved cardiac fillin

259 rats may be due to a reduction in peripheral vascular resistance since epicardial lidocaine significa

260 l hypertension is characterized by excessive vascular resistance, smooth muscle cell proliferation in

261 sly recorded and cardiac output and systemic vascular resistance (SVR) assessed at 30-minute interval

262 ncreased progressively, while spinotrapezius vascular resistance (SVR) decreased (Spinotrapezius bloo

263 e evokes either a large increase in systemic vascular resistance (SVR) or a smaller increase in SVR a

264 ns have shown an opposite effect on systemic vascular resistance (SVR), possibly confounded by barore

265 athetic activity produces greater changes in vascular resistance than tonic stimulation of the same s

266 significantly to the increased intrahepatic vascular resistance that is the primary cause of portal

267 culatory support and an increase in systemic vascular resistance that leads to reduced vasopressor us

268 g mechanisms regulating sodium excretion and vascular resistance, they generate similar haemodynamic

269 We conclude that MetS confers vascular resistance to GLP-1 receptor agonists, partiall

270 METHODS AND Systemic vascular resistance, total arterial compliance, effectiv

271 A is associated with higher total peripheral vascular resistance (TPR), and appears to be balanced by

272 her heart rate, and lower blood pressure and vascular resistance values.

273 nin-angiotensin system and directly controls vascular resistance, vessel contractility, and remodelin

274 g patterns, revealed that bursting increases vascular resistance (VR) more than tonic stimulation (57

275 Their indexed pulmonary vascular resistance was 1.8 (1.2-2.3) W/m(2), and mean p

276 Association class >/=III, and mean pulmonary vascular resistance was 11.2+/-6.4 WU.

277 x was 3.5 +/- 0.9 L/min/m(2) , and pulmonary vascular resistance was 5.6 +/- 2.8 Wood units.

278 Finally, elevated cerebral vascular resistance was a predictor of hypertension, sug

279 Causally, cerebral vascular resistance was elevated before the onset of hyp

280 ained predictive of mortality when pulmonary vascular resistance was in the normal range (p = 0.02).

281 In nonsuitable group, pulmonary vascular resistance was increased at FiO2 of 0.21 compar

282 as significantly higher (P < .01) and distal vascular resistance was lower (P = .016) after amlodipin

283 Pulmonary vascular resistance was overestimated by calculated pulm

284 In perfused FGR placentas, vascular resistance was significantly elevated compared

285 vascular resistance, but not uterine artery vascular resistance, was associated with higher childhoo

286 vascular resistance, but not utero-placental vascular resistance, was associated with slower fetal gr

287 nary artery wedge pressure and low pulmonary vascular resistance, we make a strong recommendation aga

288 Mean pulmonary artery pressure and pulmonary vascular resistance were acquired at baseline and during

289 third trimester umbilical and uterine artery vascular resistance were associated with lower fetal len

290 ssure gradient, cardiac output, and systemic vascular resistance were made at baseline and after 4 we

291 is mediated by a selective reduction in BAT vascular resistance, which greatly increases vascular pe

292 One of the hallmarks is a rise of peripheral vascular resistance, which largely depends on arteriole

293 ia is caused by a rapid decrease in systemic vascular resistance, which makes alpha-agonists the logi

294 lso induced tachycardia and loss of systemic vascular resistance, which were not seen with local appl

295 istological lung injury score, and pulmonary vascular resistance while systemic arterial pressure was

296 d right heart filling pressures and systemic vascular resistance, while increasing cardiac and stroke

297 ore, male recipients with elevated pulmonary vascular resistance who received hearts from female dono

298 However, recipients with elevated pulmonary vascular resistance who received undersized hearts had p

299 on pulmonary arterial pressure and pulmonary vascular resistance, without systemic hypotension and ve

300 323; Q = 3.82, I(2) = 21.42%), and pulmonary vascular resistance (WMD: -1.42 dyn*s/cm(5), 95%CI: -72.